|
 |
|
|||||||
|
|||||||||
© 2001 by the American Diabetes Association, Inc.
Antecedent Hyperglycemia, Not Hyperlipidemia, Is Associated With Increased Islet Triacylglycerol Content and Decreased Insulin Gene mRNA Level in Zucker Diabetic Fatty Rats
Pacific Northwest Research Institute and the Departments of Medicine and Pharmacology, University of Washington, Seattle, Washington
Type 2 diabetes is caused by a combination of ß-cell dysfunction and insulin resistance. Over time, hyperglycemia worsens, a phenomenon that has been attributed to deleterious effects of chronic hyperglycemia (glucotoxicity) or chronic hyperlipidemia (lipotoxicity) on ß-cell function and is often accompanied by increased islet triacylglycerol (TAG) content and decreased insulin gene expression. To examine these two potentially pathogenic forces, we studied Zucker rats (leptin receptor wild type, +/+; heterozygous, +/-; and mutant, -/-). First, +/+ and +/- Zucker rats were compared metabolically. At 6 weeks of age, the +/- rats had a lower level of islet insulin mRNA compared with +/+. At 12 weeks of age, differences were found in body weight and islet TAG content; however, levels of insulin mRNA were equivalent. Second, we examined whether worsening of the diabetic state in the homozygous mutant (-/-) Zucker diabetic fatty (ZDF) rat is related more to chronic hyperglycemia or to hyperlipidemia. The ZDF rats were treated for 6 weeks with either bezafibrate, a lipid-lowering drug that does not affect plasma glucose levels, or phlorizin, a drug that reduces plasma glucose without lowering lipid levels. Bezafibrate treatment lessened the rise in plasma TAG observed in nontreated rats (239 ± 16 vs. 388 ± 36 mg/dl, treated versus nontreated; P < 0.0001) but did not prevent the rise in fasting plasma glucose. Despite lowering plasma TAG, bezafibrate was not effective in preventing an increased islet TAG content and did not prevent the associated decrease in insulin mRNA levels. Phlorizin treatment prevented hyperglycemia (61 ± 2 vs. 145 ± 7 mg/dl, treated versus nontreated; P < 0.0001) and lowered islet TAG content (32.7 ± 0.7 vs. 47.8 ± 2.7 ng/islet, treated versus nontreated; P < 0.0001) and preserved insulin mRNA levels without preventing hypertriglyceridemia. Plasma free fatty acid level did not correlate with changes in islet TAG or insulin mRNA levels. We conclude that antecedent elevated plasma glucose levels, not plasma lipid levels, are associated with elevated islet TAG content and decreased insulin mRNA levels in ZDF animals.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Fujimori, K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, and M. Isaji Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 268 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Nugent, D. M. Smith, and H. B. Jones A Review of Islet of Langerhans Degeneration in Rodent Models of Type 2 Diabetes Toxicol Pathol, June 1, 2008; 36(4): 529 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Poitout and R. P. Robertson Glucolipotoxicity: Fuel Excess and {beta}-Cell Dysfunction Endocr. Rev., May 1, 2008; 29(3): 351 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Kiraly, H. E. Bates, N. A. Kaniuk, J. T. Y. Yue, J. H. Brumell, S. G. Matthews, M. C. Riddell, and M. Vranic Swim training prevents hyperglycemia in ZDF rats: mechanisms involved in the partial maintenance of {beta}-cell function Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E271 - E283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lee, M. Ravazzola, B.-H. Park, Y. K. Bashmakov, L. Orci, and R. H. Unger Metabolic Mechanisms of Failure of Intraportally Transplanted Pancreatic {beta}-Cells in Rats: Role of Lipotoxicity and Prevention by Leptin Diabetes, September 1, 2007; 56(9): 2295 - 2301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kjorholt, M. C. Akerfeldt, T. J. Biden, and D. R. Laybutt Chronic Hyperglycemia, Independent of Plasma Lipid Levels, Is Sufficient for the Loss of {beta}-Cell Differentiation and Secretory Function in the db/db Mouse Model of Diabetes Diabetes, September 1, 2005; 54(9): 2755 - 2763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang, G. Kouri, and C. B. Wollheim ER stress and SREBP-1 activation are implicated in {beta}-cell glucolipotoxicity J. Cell Sci., September 1, 2005; 118(17): 3905 - 3915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Pino, D. Z. Ye, K. D. Linning, C. D. Green, B. Wicksteed, V. Poitout, and L. K. Olson Elevated Glucose Attenuates Human Insulin Gene Promoter Activity in INS-1 Pancreatic {beta}-Cells via Reduced Nuclear Factor Binding to the A5/Core and Z Element Mol. Endocrinol., May 1, 2005; 19(5): 1343 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Alemzadeh and K. M. Tushaus Modulation of Adipoinsular Axis in Prediabetic Zucker Diabetic Fatty Rats by Diazoxide Endocrinology, December 1, 2004; 145(12): 5476 - 5484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Robertson Chronic Oxidative Stress as a Central Mechanism for Glucose Toxicity in Pancreatic Islet Beta Cells in Diabetes J. Biol. Chem., October 8, 2004; 279(41): 42351 - 42354. [Full Text] [PDF]
|
|
|
|
|
|
R. P. Robertson, J. Harmon, P. O. T. Tran, and V. Poitout {beta}-Cell Glucose Toxicity, Lipotoxicity, and Chronic Oxidative Stress in Type 2 Diabetes Diabetes, February 1, 2004; 53(90001): S119 - 124. [Abstract] [Full Text]
|
|
|
|
|
|
H. Wang, P. Maechler, P. A. Antinozzi, L. Herrero, K. A. Hagenfeldt-Johansson, A. Bjorklund, and C. B. Wollheim The Transcription Factor SREBP-1c Is Instrumental in the Development of beta -Cell Dysfunction J. Biol. Chem., May 2, 2003; 278(19): 16622 - 16629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Robertson, J. Harmon, P. O. Tran, Y. Tanaka, and H. Takahashi Glucose Toxicity in {beta}-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection Diabetes, March 1, 2003; 52(3): 581 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Laybutt, M. Glandt, G. Xu, Y. B. Ahn, N. Trivedi, S. Bonner-Weir, and G. C. Weir Critical Reduction in beta -Cell Mass Results in Two Distinct Outcomes over Time. ADAPTATION WITH IMPAIRED GLUCOSE TOLERANCE OR DECOMPENSATED DIABETES J. Biol. Chem., January 24, 2003; 278(5): 2997 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky Are Oxidative Stress-Activated Signaling Pathways Mediators of Insulin Resistance and {beta}-Cell Dysfunction? Diabetes, January 1, 2003; 52(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes Endocr. Rev., October 1, 2002; 23(5): 599 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Briaud, C. L. Kelpe, L. M. Johnson, P. O. T. Tran, and V. Poitout Differential Effects of Hyperlipidemia on Insulin Secretion in Islets of Langerhans From Hyperglycemic Versus Normoglycemic Rats Diabetes, March 1, 2002; 51(3): 662 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Poitout and R. P. Robertson Minireview: Secondary {beta}-Cell Failure in Type 2 Diabetes--A Convergence of Glucotoxicity and Lipotoxicity Endocrinology, February 1, 2002; 143(2): 339 - 342. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |